. 1997 Apr 15;94(8):4000–4004. doi: 10.1073/pnas.94.8.4000

Table 1.

Tumor responses in HBT 3477 human breast cancer xenografts in mice

Treatment	No. tumors/no. mice	Initial tumor volume, mm³ (range)	Mortality (<30 days)	No. tumor(s)			Response rate, %
Treatment	No. tumors/no. mice	Initial tumor volume, mm³ (range)	Mortality (<30 days)	PR	CR	C	Response rate, %
Control
No treatment	17/10	82 (28–146)	1	3	0	0	18
ChL6 (315 μg)	16/8	160 (55–328)	1	0	0	2	13
Taxol (600 μg)	6/5	149 (55–250)	1	0	0	0	0
Taxol (300 μg)	6/4	187 (55–273)	0	0	0	0	0
ChL6 (315 μg) + Taxol (600 μg; +24 h)	12/7	141 (50–225)	2	3	0	0	25
⁹⁰Y-ChL6	19/10	100 (44–196)	0	12	3	0	79
⁹⁰Y-ChL6 + Taxol therapy
⁹⁰Y-ChL6 + Taxol (600 μg; −72 h)	8/5	101 (39–182)	0	2	0	1	38
⁹⁰Y-ChL6 + Taxol (600 μg; −48 h)	4/3	146 (62–218)	1	2	0	1	75
⁹⁰Y-ChL6 + Taxol (300 μg; −24 h)	8/5	104 (62–164)	0	5	1	2	100
⁹⁰Y-ChL6 + Taxol (600 μg; −24 h)	9/5	146 (87–218)	0	7	0	2	100
⁹⁰Y-ChL6 + Taxol (300 μg; +6 h)	10/5	109 (44–187)	0	3	2	5	100
⁹⁰Y-ChL6 + Taxol (600 μg; + 6 h)	18/10	112 (47–237)	0	5	5	8	100
⁹⁰Y-ChL6 + Taxol (600 μg; +24 h)	18/10	90 (33–187)	0	3	6	9	100

Response rate = cure (C) + complete regression (CR) + partial regression (PR). Control mice did not receive a combination of ⁹⁰Y-ChL6 and Taxol. ⁹⁰Y-ChL6 was always at 9.6 MBq.